ArticleBiosensors & bioelectronics2026
Multimodal activity-affinity assay of ADAM-10 extracellular vesicles in untreated plasma reveals metastatic stage of colorectal cancer.
Article in Biosensors & bioelectronics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rapid and sensitive detection of cancer-derived small extracellular vesicles using Janus particles.Nature biomedical engineering · 2026Article
Corrections and comments
- Update of
Authors and funding
8 authors.
Funding
Abstract
Metalloproteinases (MPs) such as a-disintegrin and metalloproteinase-10 (ADAM-10) are key drivers of extracellular matrix remodeling during tumor progression, yet MP-based liquid biopsy tests have not reached clinical utility. Here, we show that active ADAM-10 is selectively enriched on the surface of circulating extracellular vesicles (EVs) in the plasma of colorectal cancer patients. Our findings further suggest ADAM-10+ EVs are locally enriched in dense pre-metastatic tumor extracellular matrices and subsequently accumulate in blood post-metastasis. To capture these unique signatures of disease progression, an ADAM-10 activity assay is integrated with a novel size-sensitive Immuno-Janus Particle affinity assay for characterizing ADAM-10+ EVs in untreated plasma. In a 43-patient colorectal cancer cohort, this multimodal platform distinguishes healthy, pre-metastatic, and metastatic states with 95% overall accuracy. When combined with lipidomics as a third modality, the platform correctly determines 97.4% cancer stage accuracy, with only one misclassification. This study establishes a multimodal EV-based activity/affinity assay as a robust framework for liquid biopsy, providing accurate cancer staging, improved prognostics, and offering a potential platform for pan-disease diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.